The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Durable responses to ibrutinib and venetoclax in R/R MCL: 3-year AIM update
Sasanka Handunnetti, MBBS, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, outlines the rationale and results of the AIM trial (NCT02471391), investigating the combination of ibrutinib and venetoclax in relapsed/refractory mantle cell lymphoma (MCL). Results from this three-year update are promising and demonstrate that ibrutinib in combination with venetoclax offers durable responses to patients who otherwise have limited durable therapeutic options. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
